← EPO Patent Bulletin

COMPLETELY HUMANIZED MONOCLONAL NEUTRALIZING ANTIBODY FOR TETANUS TOXIN AND APPLICATION THEREOF

Publication EP3733699A1 Kind: A1 Mar 18, 2026

Applicants

Zhuhai Trinomab Pharmaceutical Co., Ltd.

Inventors

LIAO, Huaxin, WANG, Yueming, YUAN, Xiaohui, ZHENG, Weihong

Abstract

The invention describes fully native human neutralizing monoclonalantibodies against tetanus toxin. The invention developed fully native human neutralizing monoclonalantibodies against tetanus toxin through a systematic high through-put platform that is specialized for identifying and developing human native antibody. The neutralizing monoclonal antibodies described in the invention can be used in the prevention, treatment and testing ofClostridium tetaniinfection. The fully human neutralizing monoclonal antibodies developed in the invention have a high affinity toward tetanus toxin, as well as pocessessing high neutralizing activities against the toxin, safe of use with high disease prevention effectiveness, free of exogenous virus contamination, and are widely applicable to various human groups with strong industrial applications.

IPC Classifications

C07K 16/12 20060101AFI20220429BHEP C12N 15/13 20060101ALI20220429BHEP C12N 15/85 20060101ALI20220429BHEP C12N 5/10 20060101ALI20220429BHEP A61K 39/40 20060101ALI20220429BHEP A61P 31/04 20060101ALI20220429BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR